ABL1 (E255V)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.E255V
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 2 | Dasatinib | 100.0% | 0.0% | 87.97 |
| 3 | Bosutinib | 99.6% | 0.4% | 87.22 |
| 4 | Nintedanib | 99.0% | 1.0% | 90.23 |
| 5 | Vandetanib | 97.9% | 2.1% | 95.74 |
| 6 | Canertinib | 95.9% | 4.1% | 96.49 |
| 7 | Repotrectinib | 94.8% | 5.2% | 84.21 |
| 8 | Nilotinib | 94.1% | 5.9% | 96.49 |
| 9 | Brigatinib | 93.5% | 6.5% | 82.96 |
| 10 | Axitinib | 92.5% | 7.5% | 93.23 |
| 11 | Crizotinib | 89.8% | 10.2% | 91.39 |
| 12 | Erdafitinib | 89.5% | 10.5% | 95.71 |
| 13 | Pacritinib | 87.8% | 12.2% | 88.64 |
| 14 | Dacomitinib | 86.8% | 13.2% | 97.99 |
| 15 | Tivozanib | 81.6% | 18.4% | 92.42 |
| 16 | Erlotinib | 81.6% | 18.4% | 99.75 |
| 17 | Lenvatinib | 75.0% | 25.0% | 97.74 |
| 18 | Fedratinib | 73.2% | 26.8% | 96.21 |
| 19 | Sunitinib | 70.8% | 29.2% | 91.73 |
| 20 | Alectinib | 62.3% | 37.8% | 95.49 |
| 21 | Afatinib | 61.6% | 38.4% | 98.50 |
| 22 | Entrectinib | 59.4% | 40.6% | 93.69 |
| 23 | Avapritinib | 56.3% | 43.7% | 97.73 |
| 24 | Ripretinib | 55.2% | 44.8% | 92.95 |
| 25 | Pazopanib | 53.9% | 46.1% | 97.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 100.0% | 100.0% | +0.0% |
| Dasatinib | 100.0% | 98.6% | +1.4% |
| Bosutinib | 99.6% | 99.7% | -0.2% |
| Nintedanib | 99.0% | 99.9% | -0.8% |
| Vandetanib | 97.9% | 95.7% | +2.1% |
| Canertinib | 95.9% | 91.6% | +4.3% |
| Repotrectinib | 94.8% | 93.6% | +1.2% |
| Nilotinib | 94.1% | 98.0% | -3.8% |
| Brigatinib | 93.5% | 82.8% | +10.7% |
| Axitinib | 92.5% | 99.4% | -6.9% |
| Crizotinib | 89.8% | 97.0% | -7.2% |
| Erdafitinib | 89.5% | 90.9% | -1.4% |
| Pacritinib | 87.8% | 92.0% | -4.3% |
| Dacomitinib | 86.8% | 80.8% | +6.0% |
| Tivozanib | 81.6% | 95.8% | -14.2% |
| Erlotinib | 81.6% | — | — |
| Lenvatinib | 75.0% | 76.3% | -1.3% |
| Fedratinib | 73.2% | 82.7% | -9.5% |
| Sunitinib | 70.8% | — | — |
| Alectinib | 62.3% | — | — |
| Afatinib | 61.6% | — | — |
| Entrectinib | 59.4% | — | — |
| Avapritinib | 56.3% | — | — |
| Ripretinib | 55.2% | 82.9% | -27.6% |
| Pazopanib | 53.9% | 77.5% | -23.6% |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms